-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
BioRestorative Therapies (OTCMKTS:BRTX) Earns Buy Rating From Analysts at Roth Capital
BioRestorative Therapies (OTCMKTS:BRTX) Earns Buy Rating From Analysts at Roth Capital
Roth Capital initiated coverage on shares of BioRestorative Therapies (OTCMKTS:BRTX – Get Rating) in a research report sent to investors on Wednesday, The Fly reports. The firm issued a buy rating and a $15.00 price target on the stock.
Separately, Maxim Group initiated coverage on BioRestorative Therapies in a report on Wednesday, September 28th. They issued a buy rating on the stock.
Get BioRestorative Therapies alerts:BioRestorative Therapies Price Performance
OTCMKTS BRTX opened at $3.16 on Wednesday. BioRestorative Therapies has a 1-year low of $2.46 and a 1-year high of $6.25. The business's fifty day moving average price is $3.16 and its 200-day moving average price is $3.27.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in BioRestorative Therapies stock. Cambridge Investment Research Advisors Inc. bought a new position in BioRestorative Therapies, Inc. (OTCMKTS:BRTX – Get Rating) during the first quarter, according to its most recent disclosure with the SEC. The firm bought 23,001 shares of the company's stock, valued at approximately $120,000. Cambridge Investment Research Advisors Inc. owned 0.63% of BioRestorative Therapies as of its most recent filing with the SEC. Institutional investors own 31.66% of the company's stock.BioRestorative Therapies Company Profile
(Get Rating)
BioRestorative Therapies, Inc, a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders.
Further Reading
- Get a free copy of the StockNews.com research report on BioRestorative Therapies (BRTX)
- MarketBeat: Week in Review 12/05 – 12/09
- There Is Fundamental Value In Broadcom, And It Yields 3.35%
- Costco vs Amazon: an end of the year showdown
- Discount Retailers Could Make Good Bargain Stocks
- Can Pfizer, Johnson & Johnson Continue Outperforming the Index?
Receive News & Ratings for BioRestorative Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioRestorative Therapies and related companies with MarketBeat.com's FREE daily email newsletter.
Roth Capital initiated coverage on shares of BioRestorative Therapies (OTCMKTS:BRTX – Get Rating) in a research report sent to investors on Wednesday, The Fly reports. The firm issued a buy rating and a $15.00 price target on the stock.
據The Fly報道，Roth Capital在週三發給投資者的一份研究報告中啟動了對BioRestorative Treatures(OTCMKTS：BRTX-GET Rating)股票的報道。該公司對該股發佈了買入評級和15.00美元的目標價。
Separately, Maxim Group initiated coverage on BioRestorative Therapies in a report on Wednesday, September 28th. They issued a buy rating on the stock.
另外，Maxim Group在9月28日星期三的一份報告中發起了關於生物修復療法的報道。他們對這只股票發佈了買入評級。
BioRestorative Therapies Price Performance
生物修復療法的價格表現
OTCMKTS BRTX opened at $3.16 on Wednesday. BioRestorative Therapies has a 1-year low of $2.46 and a 1-year high of $6.25. The business's fifty day moving average price is $3.16 and its 200-day moving average price is $3.27.
OTCMKTS BRTX週三開盤報3.16美元。生物修復療法的一年低點為2.46美元，一年高位為6.25美元。該業務的50日移動均線價格為3.16美元，200日移動均線價格為3.27美元。
Institutional Inflows and Outflows
機構資金流入和流出
BioRestorative Therapies Company Profile
生物修復療法公司簡介
(Get Rating)
(獲取評級)
BioRestorative Therapies, Inc, a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders.
生物修復療法公司是一家生命科學公司，專注於使用細胞和組織方案開發再生醫學產品和療法，主要涉及成人幹細胞。該公司的兩個核心開發專案與治療椎間盤/脊柱疾病和代謝紊亂有關。
Further Reading
進一步閱讀
- Get a free copy of the StockNews.com research report on BioRestorative Therapies (BRTX)
- MarketBeat: Week in Review 12/05 – 12/09
- There Is Fundamental Value In Broadcom, And It Yields 3.35%
- Costco vs Amazon: an end of the year showdown
- Discount Retailers Could Make Good Bargain Stocks
- Can Pfizer, Johnson & Johnson Continue Outperforming the Index?
- 免費獲取StockNews.com關於生物修復療法(BRTX)的研究報告
- MarketBeat：回顧一週12/05-12/09
- 博通有基本面價值，收益率為3.35%
- 好市多VS亞馬遜：年底攤牌
- 折扣零售商可以做好的便宜貨
- 輝瑞、強生能否繼續跑贏該指數？
Receive News & Ratings for BioRestorative Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioRestorative Therapies and related companies with MarketBeat.com's FREE daily email newsletter.
每天收到生物修復療法的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對BioRestorative Treatures和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧